



Federal Employee Program.

BEVACIZUMAB

Avastin (bevacizumab), Alymsys (bevacizumab-maly), Avzivi* (bevacizumab-tnjn), **Mvasi** (bevacizumab-awwb), Vegzelma (bevacizumab-adcd), **Zirabev** (bevacizumab-bvzr)

Preferred products: Mvasi, Zirabev

*This medication is included in this policy but is not available on the market as of yet

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Metastatic colorectal cancer

AND ONE of the following:

- a. 1st line treatment
 - i. Concurrent intravenous 5-Fluorouracil-based chemotherapy
- b. Treatment after 1st line with **ONE** of the following regimens:
 - 1) Fluoropyrimidine-irinotecan based chemotherapy
 - 2) Fluoropyrimidine-oxaliplatin based chemotherapy
 - 3) 5-Fluorouracil-based chemotherapy
 - 4) Trifluridine and tipiracil

2. Non-Squamous non-small cell lung cancer

- a. 1st line treatment
- b. Unresectable, locally advanced, recurrent or metastatic
- c. Concurrent therapy with carboplatin and paclitaxel

3. Glioblastoma multiforme (GBM)

- a. Single agent therapy
- b. Progressive disease following prior therapy

4. Metastatic renal cell carcinoma

- a. Concurrent therapy with interferon-alfa

5. Epithelial ovarian, fallopian tube, or primary peritoneal cancer and **ONE** of the following

- a. Initial surgical resection
 - i. Stage III or IV disease

BEVACIZUMAB

Avastin (bevacizumab), Alymsys (bevacizumab-maly), Avzivi* (bevacizumab-tnjn), **Mvasi** (bevacizumab-awwb), Vegzelma (bevacizumab-adcd), **Zirabev** (bevacizumab-bvzr)

Preferred products: Mvasi, Zirabev

*This medication is included in this policy but is not available on the market as of yet

- ii. Used in combination with paclitaxel and carboplatin for up to 6 cycles followed by bevacizumab as single agent therapy
 - b. Platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
 - i. Concurrent therapy with **ONE** of the following:
 - 1) Paclitaxel
 - 2) Pegylated liposomal doxorubicin
 - 3) Topotecan
 - c. Platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
 - i. Concurrent therapy with **ONE** of the following
 - 1) Carboplatin and paclitaxel followed by bevacizumab as a single agent
 - 2) Carboplatin and gemcitabine followed by bevacizumab as a single agent
 - d. Advanced disease
 - i. Used in combination with olaparib
 - 1) Patient has had a complete or partial response to platinum-based chemotherapy
 - 2) Cancer is associated with homologous recombination deficiency (HRD) positive status defined by at least **ONE** of the following:
 - a. Deleterious or suspected deleterious BRCA mutation
 - b. Genomic instability
6. Persistent, recurrent, or metastatic cervical cancer
- a. Concurrent therapy with **ONE** of the following:
 - i. Paclitaxel and cisplatin
 - ii. Paclitaxel and topotecan
7. Unresectable or metastatic hepatocellular carcinoma (HCC)
- a. Used in combination with atezolizumab
 - b. Patient has not received prior systemic therapy

AND the following for **ALL** indications:

1. **Non-preferred medications only:** Inadequate treatment response, intolerance, or contraindication to **ONE** of the following preferred products (Mvasi, Zirabev)



Federal Employee Program.

BEVACIZUMAB

Avastin (bevacizumab), Alymsys (bevacizumab-maly), Avzivi* (bevacizumab-tnjn), **Mvasi** (bevacizumab-awwb), Vegzelma (bevacizumab-adcd), **Zirabev** (bevacizumab-bvzr)

Preferred products: Mvasi, Zirabev

*This medication is included in this policy but is not available on the market as of yet

Avastin Only

Age 18 years of age or older

Diagnosis

Patient must have the following:

1. Ocular disease resulting from intravitreal neovascularization, including:
 - a. Neovascular (Wet) Age-Related Macular Degeneration (AMD)
 - b. Diabetic Macular Edema (DME)
 - c. Macular edema secondary to retinal vascular occlusion (RVO)
 - d. Progressive high myopia
 - e. Ocular histoplasmosis
 - f. Proliferative diabetic retinopathy
 - g. Retinopathy of prematurity (ROP)
 - h. Angioid streaks
 - i. Neovascular glaucoma (NVG)

AND the following:

1. **NOT** used in combination with other vascular endothelial growth factor (VEGF) inhibitors for ocular indications (see Appendix 1)

Prior - Approval Limits

Duration 12 months

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Metastatic colorectal cancer

AND ONE of the following:

- a. 1st line treatment
 - i. Concurrent intravenous 5-Fluorouracil-based chemotherapy

BEVACIZUMAB

Avastin (bevacizumab), Alymsys (bevacizumab-maly), Avzivi* (bevacizumab-tnjn), **Mvasi** (bevacizumab-awwb), Vegzelma (bevacizumab-adcd), **Zirabev** (bevacizumab-bvzr)

Preferred products: Mvasi, Zirabev

*This medication is included in this policy but is not available on the market as of yet

- b. Treatment after 1st line with **ONE** of the following regimens:
 - i. Fluoropyrimidine-irinotecan based chemotherapy
 - ii. Fluoropyrimidine-oxaliplatin based chemotherapy
 - iii. 5-Fluorouracil-based chemotherapy
 - iv. Trifluridine and tipiracil
- 2. Non-Squamous non-small cell lung cancer
 - a. Concurrent therapy with carboplatin and paclitaxel
- 3. Glioblastoma multiforme (GBM)
 - a. Single agent therapy
- 4. Metastatic renal cell carcinoma
 - a. Concurrent therapy with interferon-alfa
- 5. Epithelial ovarian, fallopian tube, or primary peritoneal cancer and **ONE** of the following
 - a. Status post initial surgical resection
 - i. Single agent therapy
 - b. Platinum- sensitive recurrent
 - i. Single agent therapy
 - c. Platinum-resistant recurrent
 - i. Concurrent therapy with **ONE** of the following:
 - 1) Paclitaxel
 - 2) Pegylated liposomal doxorubicin
 - 3) Topotecan
 - d. Advanced disease
 - i. Used in combination with olaparib
- 6. Persistent, recurrent, or metastatic cervical cancer
 - a. Concurrent therapy with **ONE** of the following:
 - i. Paclitaxel and cisplatin
 - ii. Paclitaxel and topotecan
- 7. Unresectable or metastatic hepatocellular carcinoma (HCC)
 - a. Used in combination with atezolizumab

Avastin Only

BEVACIZUMAB

Avastin (bevacizumab), Alymsys (bevacizumab-maly), Avzivi* (bevacizumab-tnjn), **Mvasi** (bevacizumab-awwb), Vegzelma (bevacizumab-adcd), **Zirabev** (bevacizumab-bvzr)

Preferred products: Mvasi, Zirabev

*This medication is included in this policy but is not available on the market as of yet

Age 18 years of age or older

Diagnosis

Patient must have the following:

1. Ocular disease resulting from intravitreal neovascularization, including:
 - a. Neovascular (Wet) Age-Related Macular Degeneration (AMD)
 - b. Diabetic Macular Edema (DME)
 - c. Macular edema secondary to retinal vascular occlusion (RVO)
 - d. Progressive high myopia
 - e. Ocular histoplasmosis
 - f. Proliferative diabetic retinopathy
 - g. Retinopathy of prematurity (ROP)
 - h. Angioid streaks
 - i. Neovascular glaucoma (NVG)

AND the following:

1. **NOT** used in combination with other vascular endothelial growth factor (VEGF) inhibitors for ocular indications (see Appendix 1)

Prior – Approval Renewal Limits

Same as above

Appendix 1 - List of VEGF Inhibitors for Ocular Indications

Generic Name	Brand Name
aflibercept	Eylea/Eylea HD
bevacizumab	Avastin
brolocizumab-dbl	Beovu
faricimab-svoa	Vabysmo
ranibizumab	Lucentis
ranibizumab	Susvimo